Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 10/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 4/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128941 | 0.87 | AVPR2 (0.39) | ATMATRMTORPIK3CATLR9 | |
| SCHEMBL20128993 | 0.86 | SGMS2 (0.41) | — | |
| SCHEMBL20133351 | 0.81 | ATM (0.38) | ATMATRMTORPIK3CAPRKDC | |
| SCHEMBL20129142 | 0.80 | ATM (0.30) | ATMATR | |
| SCHEMBL20129095 | 0.80 | METAP2 (0.37) | ATMATRMTORPIK3CAPRKDC | |
| SCHEMBL29547985 | 0.80 | BRD9 (0.43) | — | |
| SCHEMBL20120602 | 0.80 | BRD9 (0.43) | — | |
| SCHEMBL27097805 | 0.77 | METAP2 (0.37) | ATMATRMTORPIK3CAPDE5A | |
| SCHEMBL20128973 | 0.77 | METAP2 (0.37) | ATMATRMTORPIK3CAPDE5A | |
| SCHEMBL20129067 | 0.76 | METAP2 (0.37) | ATMATRMTORPIK3CAPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | ATM 711/4885ATR 1368/4885MTOR 765/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | ATM 959/4885ATR 1538/4885MTOR 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.